Yingye Zheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3869626/publications.pdf

Version: 2024-02-01

331670 289244 1,708 52 21 40 h-index citations g-index papers 53 53 53 2997 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Gastroenterology, 2018, 154, 2152-2164.e19.	1.3	226
2	A Model to Determine Colorectal Cancer Risk Using Common Genetic Susceptibility Loci. Gastroenterology, 2015, 148, 1330-1339.e14.	1.3	129
3	Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 344-350.	2.5	106
4	Homocysteine, cysteine, and risk of incident colorectal cancer in the Women's Health Initiative observational cohort. American Journal of Clinical Nutrition, 2013, 97, 827-834.	4.7	70
5	Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. American Journal of Preventive Medicine, 2016, 51, e107-e115.	3.0	67
6	B vitamin intakes and incidence of colorectal cancer: results from the Women's Health Initiative Observational Study cohort. American Journal of Clinical Nutrition, 2013, 97, 332-343.	4.7	64
7	The Colorectal Cancer Screening Process in Community Settings: A Conceptual Model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1147-1158.	2.5	64
8	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. European Urology, 2017, 72, 448-454.	1.9	61
9	Semiparametric estimation of time-dependent ROC curves for longitudinal marker data. Biostatistics, 2004, 5, 615-632.	1.5	58
10	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. Journal of Clinical Oncology, 2020, 38, 1549-1557.	1.6	48
11	Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. American Journal of Preventive Medicine, 2016, 51, 507-512.	3.0	46
12	Evaluating prognostic accuracy of biomarkers in nested case-control studies. Biostatistics, 2012, 13, 89-100.	1.5	45
13	Folateâ€mediated oneâ€earbon metabolism genes and interactions with nutritional factors on colorectal cancer risk: <scp>W</scp> omen's <scp>H</scp> ealth <scp>I</scp> nitiative <scp>O</scp> bservational <scp>S</scp> tudy. Cancer, 2015, 121, 3684-3691.	4.1	38
14	Impact of folic acid fortification on global DNA methylation and one-carbon biomarkers in the Women's Health Initiative Observational Study cohort. Epigenetics, 2014, 9, 396-403.	2.7	37
15	Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. Journal of the National Cancer Institute, 2020, 112, 238-246.	6.3	35
16	Determinants of Aspirin Metabolism in Healthy Men and Women: Effects of Dietary Inducers of UDP-Glucuronosyltransferases. Journal of Nutrigenetics and Nutrigenomics, 2011, 4, 110-118.	1.3	31
17	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology, 2018, 74, 211-217.	1.9	30
18	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncology, 2020, 6, e203187.	7.1	30

#	Article	IF	CITATIONS
19	A New Comprehensive Colorectal Cancer Risk Prediction Model Incorporating Family History, Personal Characteristics, and Environmental Factors. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 549-557.	2.5	25
20	Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. American Journal of Preventive Medicine, 2016, 51, e67-e75.	3.0	24
21	Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond. Preventive Medicine, 2021, 151, 106595.	3.4	23
22	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer and Prostatic Diseases, 2019, 22, 438-445.	3.9	22
23	Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. Journal of Urology, 2021, 205, 732-739.	0.4	21
24	Evaluating the Predictive Value of Biomarkers with Stratified Caseâ€Cohort Design. Biometrics, 2012, 68, 1219-1227.	1.4	20
25	Red blood cell folate and plasma folate are not associated with risk of incident colorectal cancer in the Women's Health Initiative observational study. International Journal of Cancer, 2015, 137, 930-939.	5.1	20
26	Resampling Procedures for Making Inference Under Nested Case–Control Studies. Journal of the American Statistical Association, 2013, 108, 1532-1544.	3.1	18
27	Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial. BMC Medical Genetics, 2015, 16, 18.	2.1	17
28	Receipt of Colonoscopy Following Diagnosis of Advanced Adenomas: An Analysis within Integrated Healthcare Delivery Systems. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 91-98.	2.5	16
29	Estimating Risk With Time-to-Event Data: An Application to the Women's Health Initiative. Journal of the American Statistical Association, 2014, 109, 514-524.	3.1	15
30	Assessing Accuracy of Mammography in the Presence of Verification Bias and Intrareader Correlation. Biometrics, 2005, 61, 259-268.	1.4	14
31	Association between post-treatment circulating biomarkers of inflammation and survival among stage ll–III colorectal cancer patients. British Journal of Cancer, 2021, 125, 806-815.	6.4	12
32	Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. European Urology Open Science, 2022, 37, 113-119.	0.4	10
33	Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. European Urology Oncology, 2022, 5, 430-439.	5.4	8
34	Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial. Genomics Data, 2015, 6, 154-158.	1.3	7
35	Associations between Plasma Choline Metabolites and Genetic Polymorphisms in One-Carbon Metabolism in Postmenopausal Women: The Women's Health Initiative Observational Study. Journal of Nutrition, 2020, 150, 2874-2881.	2.9	7
36	Constructing dynamic treatment regimes with shared parameters for censored data. Statistics in Medicine, 2020, 39, 1250-1263.	1.6	7

#	Article	IF	CITATIONS
37	Improving efficiency in biomarker incremental value evaluation under two-phase designs. Annals of Applied Statistics, $2017, 11, 638-654$.	1.1	6
38	Assessing Incremental Value of Biomarkers with Multi-phase Nested Case-control Studies. Biometrics, 2015, 71, 1139-1149.	1.4	4
39	Risk Projection for Time-to-Event Outcome Leveraging Summary Statistics With Source Individual-Level Data. Journal of the American Statistical Association, 0, , 1-13.	3.1	4
40	Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs. Journal of the American Statistical Association, 2018, 113, 882-892.	3.1	3
41	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer, 2022, 128, 269-274.	4.1	3
42	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Journal of Urology, 2022, 207, 805-813.	0.4	3
43	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer Medicine, 2022, , .	2.8	3
44	Two-stage biomarker panel study and estimation allowing early termination for futility. Biostatistics, 2015, 16, 799-812.	1.5	2
45	PD08-02 EVALUATING THE FOUR KALLIKREIN PANEL OF THE 4KSCORE FOR PREDICTION OF HIGH-GRADE PROSTATE CANCER IN MEN IN THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS). Journal of Urology, 2016, 195, .	0.4	2
46	Learningâ€based biomarkerâ€assisted rules for optimized clinical benefit under a risk constraint. Biometrics, 2020, 76, 853-862.	1.4	2
47	Reâ€calibrating pure risk integrating individual data from twoâ€phase studies with external summary statistics. Biometrics, 2022, 78, 1515-1529.	1.4	2
48	Associations between Genetic Variants and Blood Biomarkers of One-Carbon Metabolism in Postmenopausal Women from the Women's Health Initiative Observational Study. Journal of Nutrition, 2022, 152, 1099-1106.	2.9	2
49	Developing and evaluating risk prediction models with panel current status data. Biometrics, 2021, 77, 599-609.	1.4	1
50	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. Journal of Urology, 0, , .	0.4	1
51	OUP accepted manuscript. Biostatistics, 2021, , .	1.5	0
52	Targeted Search for Individualized Clinical Decision Rules to Optimize Clinical Outcomes. Statistics in Biosciences, 0, , .	1.2	0